0914 ET - Restaurant executives are watching for signs of slower sales as more Americans take GLP-1 weight loss drugs, but Burger King owner Restaurant Brands International thinks it's prepared to meet any demand shift. Weight-loss drug users often seek out protein while using the medications, and Burger King's products are protein rich, CEO Josh Kobza said during an investor event. The chain's Double Cheeseburger is a smaller size with a high meat to bread ratio, making it a potential draw for GLP-1 users, Kobza says. (heather.haddon@wsj.com; @heatherhaddon)
(END) Dow Jones Newswires
December 03, 2025 09:15 ET (14:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments